Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

United Therapeutics Corporation

35 indications, side-by-side phase, drug & LoA

$545.96

+0.56 (+0.1%)

A 83Pipeline Score Undervalued Biotech · Commercial
Market Cap
24.13 B
EPS
29.33
P/E Ratio
20.98 $
Value Trade
178.76 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    781.50 M

  • R&D Expenses

    138.20 M

  • Operating CF

    463.30 M

  • Total Assets

    6.71 B

  • Total Liabilities

    813.10 M

  • Equity

    5.90 B

  • D/E Ratio

    12,345

-1.4 %
Week
-0.92 %
1 Month
18.64 %
3 Month
20.08 %
6 Month
196.46 %
5 Year
8,321.19 %
All Time
Cash Data
Profitable

  • Cash Position

    2.15 B

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 6, 2026
Overview
Volume
451.83 K
52 Week Range
272.12 - 609.35
% held by Insiders
3.33 %
% held by Institutions
99.11 %
Enterprise Value
21.97 B
Total Shares
43.07 M
Short %
5.26 %
Float Shares
41.69 M
Company Description
HQ: 1000 SPRING ST, SILVER SPRING,...
Employees:1,400
https://www.unither.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 3 data readout example
Tyvaso® (treprostinil) inhalation solution Idiopathic pulmonary fibrosis (IPF)
Phase 3
—
Small Molecules
Respiratory System
Tyvaso® (treprostinil) inhalation solution Idiopathic pulmonary fibrosis (IPF)
Phase 3
—
Small Molecules
Respiratory System
Tyvaso® (treprostinil) inhalation solution Idiopathic pulmonary fibrosis (IPF)
Phase 3
—
Small Molecules
Respiratory System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
A83
Pipeline Score
$30.4B
Pipeline Value
Undervalued
Valuation Signal
87
Drugs Scored
4.2x
rNPV / MCap
Top 98%
Mid Cap
(rank 19 of 905)
Percentile Rank
United Therapeutics Corporation earns an A-grade pipeline score (83/100), with $35.8B risk-adjusted pipeline value, led by ALVAC-HIV vCP1521 + AIDSVAX in HIV Infection (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
ALVAC-HIV vCP1521 + AIDSVAX
Monoclonal antibody		HIV InfectionPhase 3NCT0022308072% $7.0B COMPLETED 16,402 - -Jun 1, 2009 -Apr 24, 2019
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
ralinepag
pulmonary arterial hypertension
Phase 3
2025-06-23
ralinepag
pulmonary arterial hypertension
Phase 3
2025-06-23
ralinepag
pulmonary arterial hypertension
Phase 3
2025-06-23
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in UTHR
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
UTHR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
UTHR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
UTHR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
UTHR Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
UTHR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-11-20 0.00 0 - - - - - -
2026-11-20 0.00 0 - - - - - -
2026-11-20 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest United Therapeutics Corporation (UTHR) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How UTHR ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Pulmonary Arterial Hypertension #1 of 13 PHASE 3 Ralinepag
MRK INSM JNJ
$8.48B 0.88 LEADER
General Respiratory Disorders #1 of 6 PHASE 3 Ralinepag
AZN EW ·dev GEHC ·dev
—0.85 LEADER
Respiratory Disorders #1 of 5 PHASE 3 Ralinepag
AZN ISRG ·dev MASI
—0.85 LEADER
Skin Injuries #1 of 3 PHASE 2 cP12
RCEL CTSO
—0 LEADER
General Cardiovascular Diseases #2 of 16 PHASE 3 Ralinepag
LLY EW ·dev ABT ·dev
—0.85 CONTENDER
Interstitial Lung Disease #2 of 12 PHASE 3 Treprostinil
GSK INSM BMY
$8.91B 0.75 CONTENDER
Idiopathic Pulmonary Fibrosis #2 of 12 PHASE 3 Treprostinil
BMY PRTC ABBV
$4.87B 0.7 CONTENDER
Tendinopathy #2 of 3 PHASE 1 Metformin
ZBH ·dev TFX ·dev
 $240.12B 0 CONTENDER
Hypertension #4 of 16 PHASE 3 Ralinepag
LLY ALNY MLYS
$9.41B 0.85 CONTENDER
Open-Angle Glaucoma #4 of 5 PHASE 4 Nicotinomide
GKOS AMRX ABBV
$8.99B 0 CONTENDER
Atherosclerosis #7 of 15 PHASE 3 Ralinepag
NVO NVS LLY
$35.43B 0.85 CONTENDER
COPD #9 of 13 PHASE 2 Treprostinil
GSK AZN SNY
$46.93B 0 FOLLOWER
Chronic Pain #10 of 17 PHASE 1 Metformin
LLY BSX ·dev ZBH ·dev
 $91.35B 0 FOLLOWER
Myeloproliferative Neoplasms #14 of 14 PHASE 2 bomedemstat
BMY ABBV NVS
—0 FOLLOWER
Chronic Kidney Disease #15 of 27 PHASE 1 10 GE Xenokidney
AZN LLY NVO
$96.33B 0.84 FOLLOWER
Liver Cancer #28 of 37 PHASE 2 Atezolizumab + Cabozantinib + Lenvatinib
AZN BMY EXEL
$4.8B 0 FOLLOWER